Princeton, New Jersey, September 16, 2014 – The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is pleased to announce that Nancy S. Berg will join the Society on October 22, 2014, as its CEO and Executive Director, succeeding ISPOR Founding Executive Director, Marilyn Dix Smith, RPh, PhD who announced plans to retire in 2013. Berg joins ISPOR, the world’s leading organization promoting the science of pharmacoeconomics and outcomes research, following an extensive career at the helm of two leading technical and scientific associations.
[caption id="" align="alignleft" width="138"]
Nancy S. Berg[/caption]
“The role of ISPOR has never been more important to the global health care community, including researchers, clinicians, health technology developers, assessors, and decision makers,” said Berg. “I am proud to be joining at a time when the work of ISPOR and its members is more critical than ever and look forward to contributing my career experience to the Society’s future success.”
As Executive Director of the Society of Manufacturing Engineers, a global association of engineering and scientific professionals, Berg led exponential growth in their education/trade events and the Society’s global expansion through partnerships, joint ventures and other alliances. She also consulted with nonprofit and commercial businesses on strategic growth, good governance and leadership.
Most recently, Berg was President & CEO of the International Society for Pharmaceutical Engineering (ISPE) where she led transformational change in this global professional society and fostered dialog and education on technical, scientific and regulatory best practices in the pharmaceutical and biotech industries. ISPE credits Berg with being instrumental in creating synergies between pharmaceutical industry stakeholders, bringing together diverse groups of professionals, regulators, and partner organizations to work on issues of shared concern. Noteworthy contributions to ISPE include leading teams of ISPE Members to complete groundbreaking research recently cited by the FDA in its drug shortages strategic plan and in senior official U.S. Congressional testimony. Other industry collaboration spearheaded by Berg involves ISPE members and regulators in Europe and North America and includes ISPE's current Quality Metrics Study, conducted to help identify a set of common metrics for use by industry and health authorities in assessing product quality and patient safety.
“We are delighted that Nancy Berg will join ISPOR as its new CEO and Executive Director.” said Adrian Towse, MA, MPhil, 2014-2015 ISPOR President.
“Under Berg’s leadership, we anticipate ISPOR will strengthen in value to its members and continue to serve as a catalyst for communication between all health care stakeholders.” said Bill Crown, PhD, 2014-2015 ISPOR Past-President.